Adding the T-Cell Booster Decitabine to Anti–PD-1 Therapy in Hodgkin Lymphoma


Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.

The addition of the T cell–boosting decitabine to anti–programmed death 1 (PD-1) therapy with camrelizumab resulted in a significantly increased rate of complete remission (CR) compared with camrelizumab alone among patients with relapsed or refractory classic Hodgkin lymphoma, according to the results of a phase II study.

“At present, the CR rate with anti–PD-1 monotherapy in patients with heavily pretreated relapsed/refractory classic Hodgkin lymphoma is generally 20% to 30%,” wrote researcher Jing Nie, PhD, of Chinese People’s Liberation Army General Hospital, and colleagues, in the Journal of Clinical Oncology. “To our knowledge, we now report the largest cohort of patients with relapsed/refractory classic Hodgkin lymphoma who were treated with combination anti–PD-1 and DNA demethylating agent with an extremely high CR rate of 71%.”

According to the study, prior research had shown that DNA methylation inhibition enhanced PD-1 blockade-mediate T-cell rejuvenation.

“PD-1 blockade can reinvigorate exhausted T cells by disrupting the binding of PD-1 with PD-L1 on tumors or other immune-suppressive cells,” the researchers wrote. “However, exhausted T cells possess a distinct epigenetic profile compared with effector and memory T cells and are not remodeled by PD-1 blockade. This could limit the long-lasting antitumor ability of anti–PD-1 antibodies. Low-dose decitabine could alter the epigenetic status of both tumors and immunocytes.”

Therefore, in this study, Nie and colleagues tested whether the addition of DNA demethylating decitabine could boost the activity of the anti–PD-1 camrelizumab.

The study included 86 patients with relapsed or refractory chronic Hodgkin lymphoma who had received at least 2 lines of prior therapy. Patients were assigned 1:2 to camrelizumab monotherapy or decitabine plus camrelizumab. Any patient with prior anti–PD-1 therapy was assigned to the combination arm.

With a median follow-up of 14.9 months, the CR rate was more than double among anti–PD-1 naive patients assigned to combination therapy compared with monotherapy (71% vs 32%; P = .003). Response duration at 6 months was 100% in patients assigned to combination therapy compared with 76% among those assigned to monotherapy.

Among those patients with prior exposure to anti–PD-1 therapy, the CR rate was 28%, and the partial remission rate was 24% after combination therapy. Ten patients maintained response at 6 months, and the majority (81%) of responders maintained response at more than 1 year.

Five patients (26%) reported immune-related adverse events on monotherapy, including hypothyroidism, pneumonitis, and hypersensitivity. Twenty (30%) patients on the combination arm reported immune-related adverse events, the most common of which were myalgia, rash, diarrhea, and hypothyroidism.

“As appropriate immune activation is required for immune-based therapies, the epigenetic modifying agent decitabine could promote T-cell activation and may strengthen the effectiveness and duration of clinical responses with anti–PD-1 antibodies,” the researchers concluded.

Related Videos
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
This series features 2 KOLs.
This series features 2 KOLs.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
This series features 2 KOLs.
This series features 2 KOLs.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Related Content